Medical Pharmacology: Chapter 36 — Antiviral Pharmacology -- Module 8

Chapter 36 — Antiviral Pharmacology — Module 8 — Antiviral Resistance Principles

1. Why do ribonucleic acid (RNA) viruses generate drug-resistant variants at far higher rates than the cells they infect?

A) Their genomes are physically larger, so each replication cycle copies more nucleotides and accumulates proportionally more total errors.
B) They integrate into host deoxyribonucleic acid (DNA) and inherit the host cell's mutation rate during cell division.
C) Their RNA-dependent RNA polymerases lack the 3'-to-5' exonuclease proofreading activity present in cellular DNA polymerases, raising the per-nucleotide error rate by several orders of magnitude.
D) They replicate exclusively in immune-privileged tissues where host repair enzymes cannot reach the viral genome.
E) They preferentially recombine with endogenous retroviral sequences, importing pre-existing resistance mutations from the host genome.

ANSWER: C

Rationale:

Option C is correct. RNA viruses replicate with RNA-dependent RNA polymerases (RdRp) that lack the 3'-to-5' exonuclease proofreading function of cellular DNA polymerases. This produces mutation rates of roughly 10^-4 to 10^-6 substitutions per nucleotide per replication cycle — six to ten orders of magnitude higher than cellular DNA replication — so resistant variants are generated continuously even before any drug is given.

Option A: Option A is incorrect. RNA viral genomes are typically far smaller than the host genome, not larger; the high mutation rate is a function of polymerase fidelity, not genome size.
Option B: Option B is incorrect. Most RNA viruses do not integrate into host DNA, and the high mutation rate comes from the error-prone viral polymerase rather than from inheriting the host's (low) mutation rate.
Option D: Option D is incorrect. Replication site does not explain the mutation rate; error-prone RdRp activity does, and it operates wherever the virus replicates.
Option E: Option E is incorrect. Resistance arises from polymerase errors during replication, not from recombination importing host-derived resistance mutations.

2. The quasispecies model of viral populations changes how clinicians interpret drug resistance. Which statement best captures its central implication?

A) Resistant variants generally pre-exist as a minority within the viral swarm before therapy begins and are selected to dominance by drug pressure, rather than arising de novo only after drug exposure.
B) Each infected host carries a single genetically uniform viral clone, so resistance must be acquired entirely after the drug is started.
C) Resistance can develop only after a drug is administered, because the drug itself is mutagenic to the viral polymerase.
D) The viral population is shaped primarily by host antibody pressure, making drug selection largely irrelevant to which variants dominate.
E) Resistant variants are eliminated faster than they arise, so clinically meaningful resistance essentially never emerges within a single host.

ANSWER: A

Rationale:

Option A is correct. A quasispecies is a dynamic swarm of closely related but genetically distinct genomes distributed around a dominant consensus sequence. Because high mutation rates continuously generate diversity, drug-resistant variants typically pre-exist at low frequency before therapy; the drug eliminates susceptible wild-type virus and the pre-existing resistant minority expands to dominance.

Option B: Option B is incorrect. The defining feature of a quasispecies is genetic heterogeneity, not a uniform clone; resistance does not have to be acquired entirely after treatment starts.
Option C: Option C is incorrect. Antiviral drugs select pre-existing variants; they are not mutagens that create resistance by damaging the polymerase.
Option D: Option D is incorrect. Drug selection is precisely what drives resistant variants to dominance; the quasispecies model centers on drug (and immune) selection acting on standing diversity.
Option E: Option E is incorrect. Resistant minority variants present at even 1% to 20% can rapidly dominate under drug pressure, especially when fitness cost is low — the opposite of never emerging.

3. In antiviral resistance biology, what is meant by the "fitness cost" of a resistance mutation?

A) The financial cost of the additional drugs required once a resistance mutation is detected in a patient.
B) The increase in viral pathogenicity that accompanies acquisition of a resistance mutation.
C) The probability that two independent resistance mutations will arise simultaneously in the same genome.
D) The reduction in viral replicative capacity conferred by the mutation in the absence of drug.
E) The host immune effort, measured in cytotoxic T-cell activity, required to clear a resistant variant.

ANSWER: D

Rationale:

Option D is correct. Fitness cost is the reduction in replicative capacity that a resistance mutation imposes on the virus when no drug is present. A mutation that distorts the target enzyme's active site lowers replication efficiency, so the resistant variant is outcompeted by wild-type once drug pressure is removed; a mutation that alters drug binding without disrupting catalysis carries little fitness cost and can persist or spread.

Option A: Option A is incorrect. Fitness cost is a virologic/evolutionary property of the mutation, not a measure of drug expenditure.
Option B: Option B is incorrect. Fitness cost refers to replicative capacity, not pathogenicity, and resistance mutations more often reduce fitness than increase virulence.
Option C: Option C is incorrect. The joint probability of two simultaneous mutations is a separate concept underlying combination therapy, not the definition of fitness cost.
Option E: Option E is incorrect. Fitness cost is defined in the absence of drug by replicative capacity, not by the magnitude of the host immune response.

4. What is the core pharmacological rationale for using combination antiviral therapy against a high-mutation-rate RNA virus?

A) Each additional drug lowers the dose of every other drug, reducing dose-dependent toxicity enough to permit lifelong therapy.
B) A virus must carry resistance mutations to every drug simultaneously to replicate, and the probability of one genome holding multiple independent resistance mutations is approximately the product of the individual mutation frequencies — a vanishingly small number.
C) Combining drugs slows hepatic metabolism so that each agent reaches higher plasma concentrations than it would alone.
D) Multiple drugs taken together are mutagenic to the virus in a way that single agents are not, accelerating error catastrophe.
E) Using several drugs guarantees that at least one will be a nucleoside analog, which is the only class capable of suppressing RNA viruses.

ANSWER: B

Rationale:

Option B is correct. To replicate against two drugs hitting different targets, a virus must simultaneously carry resistance mutations at both. Because the events are approximately independent, the joint probability is roughly the product of the individual frequencies (for example, 10^-5 x 10^-5 = 10^-10); a third target drives this to roughly 10^-15. This raises the genetic barrier above the pathogen's daily productive capacity, which is why triple therapy anchors HIV treatment and high-barrier combinations anchor hepatitis C virus (HCV) regimens.

Option A: Option A is incorrect. Combination therapy is used to raise the genetic barrier to resistance, not primarily to lower per-drug dosing for toxicity reasons.
Option C: Option C is incorrect. While pharmacokinetic boosting exists for specific agents, the general rationale for combination therapy is the multiplicative genetic barrier, not slowed metabolism of all agents.
Option D: Option D is incorrect. Standard combination therapy works by selection against multiply-resistant genomes, not by acting as a mutagen; error-catastrophe (lethal mutagenesis) is a distinct mechanism specific to certain agents.
Option E: Option E is incorrect. Effective combinations are built from mechanistically distinct classes; there is no requirement that one be a nucleoside analog.

5. The lamivudine resistance mutation M184V/I (methionine-to-valine/isoleucine at position 184) in HIV reverse transcriptase is often described as carrying a high fitness cost. What clinical behavior follows from that high fitness cost?

A) Once selected, M184V/I spreads readily as transmitted resistance because it improves viral replicative capacity.
B) M184V/I confers broad cross-resistance across every nucleoside and non-nucleoside reverse transcriptase inhibitor class.
C) M184V/I is undetectable by standard genotypic testing because it does not change the amino acid sequence.
D) M184V/I converts the virus to a hypermutator phenotype, accelerating emergence of further resistance.
E) Because the mutation reduces replicative capacity, the resistant variant tends to be outcompeted and resuppressed once lamivudine pressure is removed.

ANSWER: E

Rationale:

Option E is correct. M184V/I confers high-level lamivudine and emtricitabine resistance but imposes a substantial fitness cost on HIV reverse transcriptase. In the absence of drug pressure, the more-fit wild-type virus outcompetes the M184V/I variant, so the mutation typically falls back below detection after the selecting drug is stopped in most patients.

Option A: Option A is incorrect. A high fitness cost makes a mutation less likely to spread without drug pressure; M184V/I reduces, not improves, replicative capacity.
Option B: Option B is incorrect. M184V/I is a discrimination mutation conferring high-level resistance principally to lamivudine and emtricitabine, not broad cross-resistance across all reverse transcriptase inhibitor classes.
Option C: Option C is incorrect. M184V/I is an amino-acid-changing substitution that standard genotyping detects readily.
Option D: Option D is incorrect. M184V/I does not create a hypermutator phenotype; if anything it modestly increases replication fidelity.

6. The adamantane resistance mutation S31N (serine-to-asparagine at position 31) in the influenza matrix protein 2 (M2) ion channel became globally prevalent even in untreated populations. Which property best explains this spread?

A) S31N is repeatedly re-selected in each patient because adamantanes remain the most widely prescribed influenza antivirals worldwide.
B) S31N imposes essentially no fitness cost, so the resistant variant replicates as efficiently as wild-type and spreads even without ongoing drug pressure.
C) S31N enhances neuraminidase activity, giving the virus a transmission advantage independent of the M2 channel.
D) S31N can only persist in immunocompromised hosts, who serve as a continuous reservoir reseeding the global population.
E) S31N reverts rapidly whenever drug pressure is absent, so its prevalence reflects constant new drug exposure rather than true spread.

ANSWER: B

Rationale:

Option B is correct. S31N alters the adamantane binding site of the M2 channel without meaningfully impairing channel function, so it carries near-zero fitness cost. A resistant variant that replicates as well as wild-type is not outcompeted when drug pressure is absent, which is why adamantane-resistant influenza became globally dominant independent of drug use — the contrasting case to high-fitness-cost mutations such as M184V/I.

Option A: Option A is incorrect. Adamantanes are no longer recommended for influenza precisely because resistance is near-universal; ongoing prescribing does not explain the spread.
Option C: Option C is incorrect. S31N is an M2 channel mutation; it does not act by enhancing neuraminidase activity.
Option D: Option D is incorrect. The low fitness cost lets the variant persist in the general immunocompetent population, not merely in immunocompromised reservoirs.
Option E: Option E is incorrect. Low fitness cost means the variant does not rapidly revert when drug is withdrawn; that is the essence of why it spread.

7. Which description best characterizes genotypic resistance testing?

A) It sequences the viral genome at drug-target regions and compares detected mutations against a curated database of substitutions known or predicted to reduce drug susceptibility.
B) It grows the patient's virus in cell culture across a range of drug concentrations and reports the fold-change in inhibitory concentration relative to a reference strain.
C) It measures serum drug levels to determine whether subtherapeutic exposure, rather than true resistance, explains treatment failure.
D) It quantifies total plasma viral load to confirm that the patient is failing therapy before any sequence analysis is undertaken.
E) It detects host human leukocyte antigen alleles that predict hypersensitivity to specific antiviral agents.

ANSWER: A

Rationale:

Option A is correct. Genotypic testing sequences viral drug-target genes — for HIV, the reverse transcriptase, protease, and integrase genes (plus envelope when entry inhibitors are planned) — and interprets the detected mutations against curated resistance databases. Turnaround is typically 1 to 3 weeks, and standard Sanger sequencing reliably detects mutations present in more than about 15% to 20% of the population.

Option B: Option B is incorrect. That describes phenotypic testing, which measures replication across drug concentrations and reports fold-change in IC50.
Option C: Option C is incorrect. Measuring drug levels assesses pharmacokinetic failure, not the viral genotype.
Option D: Option D is incorrect. Viral load quantifies the degree of replication/failure but does not identify resistance mutations.
Option E: Option E is incorrect. Host genetic testing (for example, for hypersensitivity risk) is a pharmacogenomic test, not viral resistance genotyping.

8. A patient's standard Sanger genotype shows no resistance mutations, yet the clinician is concerned about pre-existing minority resistant variants. What is the key difference between standard sequencing and next-generation sequencing (NGS) relevant to this concern?

A) Standard Sanger sequencing detects only integrase mutations, whereas NGS is required to detect reverse transcriptase mutations.
B) Standard sequencing reports phenotype while NGS reports genotype, so the two cannot be compared directly.
C) Standard Sanger sequencing reliably detects variants present above roughly 15% to 20% of the population, whereas NGS (deep sequencing) can detect minority variants down to about 1%.
D) NGS can only be performed on cultured virus, so it cannot be used on plasma samples the way Sanger sequencing can.
E) Standard sequencing detects variants down to about 1%, while NGS is a lower-resolution screen used only for population surveillance.

ANSWER: C

Rationale:

Option C is correct. Conventional Sanger sequencing — the historical gold standard — reliably detects mutations present in more than about 15% to 20% of the viral population; minority variants below that threshold are missed. NGS (deep or ultra-deep sequencing) can detect variants down to roughly 1%, increasing sensitivity for pre-existing resistance that could expand under drug pressure, though the clinical significance of variants below about 5% is still under investigation.

Option A: Option A is incorrect. Both methods can sequence the same target genes; the distinction is sensitivity to minority variants, not which gene is covered.
Option B: Option B is incorrect. Both Sanger and NGS are genotypic methods; neither reports a culture-based phenotype.
Option D: Option D is incorrect. NGS is routinely performed on plasma-derived viral nucleic acid and does not require cultured virus.
Option E: Option E is incorrect. This inverts the two methods; it is NGS, not standard sequencing, that reaches the ~1% detection threshold.

9. How does phenotypic resistance testing express its result, and when is it most useful?

A) It sequences the protease gene and reports a list of mutations, making it the fastest and cheapest first-line test for newly diagnosed patients.
B) It reports the percentage of the viral population carrying a given mutation, and is most useful for detecting transmitted resistance at diagnosis.
C) It measures host antibody titers against the virus and is most useful for confirming vaccine response.
D) It measures the virus's ability to replicate across increasing drug concentrations, reporting the fold-change in the 50% inhibitory concentration (IC50) versus a reference strain, and is most valuable for highly mutated viruses in treatment-experienced patients.
E) It reports plasma drug concentration as a fold-change from the target trough, and is most useful for confirming adherence.

ANSWER: D

Rationale:

Option D is correct. Phenotypic testing grows the patient's virus in culture across a range of drug concentrations and reports the fold-change in IC50 relative to a susceptible reference strain, compared against established clinical cutoffs. It is particularly valuable for heavily treatment-experienced patients whose multiple interacting mutations produce complex patterns that genotypic interpretation rules struggle to predict; its drawbacks are longer turnaround (3 to 4 weeks), higher cost, and technical complexity.

Option A: Option A is incorrect. Sequencing and reporting a mutation list describes genotypic testing; phenotype is slower and costlier, not the cheapest first-line option.
Option B: Option B is incorrect. Reporting mutation frequency is a feature of genotypic/NGS testing, not phenotypic assays.
Option C: Option C is incorrect. Phenotypic resistance testing measures viral replication against drug, not host antibody titers.
Option E: Option E is incorrect. Phenotype measures viral replication versus drug concentration, not plasma drug levels for adherence.

10. An HIV patient is failing therapy with a confirmed plasma HIV ribonucleic acid (RNA) above 200 copies per milliliter. Why is it important to obtain the resistance genotype while the patient is still taking the failing regimen?

A) Drug pressure must be present for the sequencing reaction to amplify viral nucleic acid; samples drawn off-therapy cannot be sequenced.
B) Once the selecting drug is stopped, the more-fit wild-type virus re-emerges as the dominant population and the resistance mutations that drove failure may fall below the detection threshold of standard genotyping.
C) Resistance mutations are only transcribed into RNA while the drug is present, so they physically disappear from the genome off-therapy.
D) Stopping therapy before testing causes the viral load to rise so high that the assay is saturated and uninterpretable.
E) Insurance reimbursement rules require that genotyping occur only during active treatment, independent of any virologic rationale.

ANSWER: B

Rationale:

Option B is correct. Resistance testing should ideally be performed on the failing regimen because resistant variants are maintained at detectable levels by ongoing drug selection. Once the selecting drug is withdrawn, fitter wild-type virus rapidly outcompetes the resistant population, and the driving mutations can drop below the roughly 15% to 20% detection threshold of standard genotyping within weeks — potentially masking clinically important resistance.

Option A: Option A is incorrect. Sequencing does not require drug pressure to amplify viral nucleic acid; the issue is which variants dominate, not whether amplification works.
Option C: Option C is incorrect. Resistance mutations are encoded in the viral genome and do not physically vanish off-therapy; they simply become a minority population.
Option D: Option D is incorrect. The concern is loss of the resistant minority below detection, not assay saturation from high viral load.
Option E: Option E is incorrect. The rationale is virologic (selection dynamics), not a reimbursement rule.

11. Nucleoside reverse transcriptase inhibitor (NRTI) resistance in HIV arises by two distinct mechanisms: discrimination and excision. The M184V/I mutation is the archetype of which mechanism, and what does that mechanism do?

A) Excision — it enhances pyrophosphorolytic removal of the incorporated chain-terminator, restoring chain elongation.
B) Excision — it accelerates host kinase activation of the drug, paradoxically increasing intracellular triphosphate levels.
C) Discrimination — it reduces the reverse transcriptase's ability to incorporate the NRTI triphosphate relative to the natural deoxynucleoside triphosphate substrate.
D) Discrimination — it prevents the drug from ever being phosphorylated to its active triphosphate form by cellular kinases.
E) Recombination — it swaps in a resistant polymerase domain from a co-infecting viral strain.

ANSWER: C

Rationale:

Option C is correct. Discrimination mutations reduce the enzyme's ability to incorporate the NRTI triphosphate relative to the natural deoxynucleoside triphosphate (dNTP). M184V/I is the archetypal discrimination mutation, conferring high-level lamivudine and emtricitabine resistance with only modest loss of replicative capacity.

Option A: Option A is incorrect. Enhanced pyrophosphorolytic removal of the chain-terminator describes the excision mechanism (thymidine analog mutations), not M184V/I.
Option B: Option B is incorrect. Excision does not act by increasing host kinase activation of the drug; this description is mechanistically wrong.
Option D: Option D is incorrect. M184V/I acts at the incorporation step within reverse transcriptase, not by blocking cellular kinase activation of the prodrug.
Option E: Option E is incorrect. M184V/I is a point mutation acting by discrimination, not a recombination event importing a foreign polymerase domain.

12. Thymidine analog mutations (TAMs) are the principal excision-type resistance mutations in HIV reverse transcriptase. What is their mechanism and clinical consequence?

A) They block cellular phosphorylation of thymidine analogs, so only non-thymidine NRTIs remain affected.
B) They increase the binding affinity of non-nucleoside reverse transcriptase inhibitors, producing cross-resistance limited to that class.
C) They are discrimination mutations that selectively impair incorporation of lamivudine while sparing all other agents.
D) They chelate the magnesium ions required by integrase, conferring resistance to integrase strand transfer inhibitors.
E) They enhance the enzyme's pyrophosphorolytic removal of the incorporated chain-terminating nucleotide, restoring chain elongation and producing broad NRTI cross-resistance as they accumulate.

ANSWER: E

Rationale:

Option E is correct. TAMs act by the excision mechanism: they enhance reverse transcriptase's ability to remove the incorporated chain-terminating NRTI through pyrophosphorolysis, allowing chain elongation to resume. As TAMs accumulate, they produce broad cross-resistance across the NRTI class.

Option A: Option A is incorrect. TAMs act on the enzyme's excision activity, not by blocking cellular phosphorylation of thymidine analogs.
Option B: Option B is incorrect. TAMs affect NRTIs through excision; they do not increase non-nucleoside inhibitor binding or confine resistance to that class.
Option C: Option C is incorrect. Selective impairment of lamivudine incorporation describes the discrimination mutation M184V/I, not the excision-type TAMs.
Option D: Option D is incorrect. Magnesium chelation at integrase is the target of integrase strand transfer inhibitors; TAMs operate within reverse transcriptase.

13. Why are first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as efavirenz and nevirapine considered to have a low genetic barrier to resistance?

A) A single mutation in the NNRTI binding pocket — such as K103N (lysine-to-asparagine at position 103) — alters the pocket geometry enough to confer high-level resistance across the first-generation NNRTIs at once.
B) They require three or more accumulated active-site mutations before any loss of susceptibility occurs.
C) They are prodrugs whose activation depends on a single host enzyme that is frequently absent.
D) Their resistance depends entirely on excision (pyrophosphorolysis), which arises slowly over years of therapy.
E) Resistance requires simultaneous mutation of both the binding pocket and the integrase active site.

ANSWER: A

Rationale:

Option A is correct. First-generation NNRTIs bind a hydrophobic pocket adjacent to the reverse transcriptase active site. Because a single substitution — K103N, Y181C, or G190A — distorts that pocket, one mutation can confer high-level resistance across the whole first-generation class, which is the definition of a low genetic barrier. Second-generation NNRTIs (etravirine, rilpivirine) have more binding flexibility and tolerate single mutations better.

Option B: Option B is incorrect. Needing three or more accumulated mutations describes a high-barrier agent; first-generation NNRTIs fail with a single mutation.
Option C: Option C is incorrect. NNRTIs are not prodrugs requiring activation; they bind the enzyme directly.
Option D: Option D is incorrect. NNRTI resistance is conferred by binding-pocket mutations, not by the excision mechanism that underlies certain NRTI resistance.
Option E: Option E is incorrect. A single binding-pocket mutation suffices; simultaneous integrase mutation is not required.

14. Second-generation integrase strand transfer inhibitors (INSTIs) such as dolutegravir and bictegravir differ from first-generation agents (raltegravir, elvitegravir) in their resistance behavior. Which statement is correct?

A) Second-generation INSTIs are vulnerable to the same single signature mutations (N155H, Q148H) that defeat first-generation agents.
B) Second-generation INSTIs require host kinase activation, giving them a uniquely low barrier to resistance.
C) First-generation INSTIs have the higher genetic barrier, while second-generation agents fail after a single mutation.
D) Second-generation INSTIs have a higher genetic barrier, generally requiring accumulation of two or more resistance mutations to meaningfully reduce susceptibility, and treatment-emergent resistance is rare in INSTI-naive patients.
E) Both generations have identical resistance barriers; the distinction is purely one of dosing frequency.

ANSWER: D

Rationale:

Option D is correct. Second-generation INSTIs (dolutegravir, bictegravir, cabotegravir) have higher genetic barriers, typically requiring two or more accumulated mutations to meaningfully reduce susceptibility. Emergent INSTI resistance with dolutegravir is rare in INSTI-naive patients and has mainly been described with complex treatment histories or subtherapeutic levels.

Option A: Option A is incorrect. The single signature mutations (N155H, Q148H/R/K, Y143C/R) primarily defeat first-generation INSTIs; second-generation agents resist them better.
Option B: Option B is incorrect. INSTIs are not prodrugs requiring host kinase activation, and second-generation agents have a high, not low, barrier.
Option C: Option C is incorrect. This inverts the generations — second-generation agents carry the higher barrier.
Option E: Option E is incorrect. The generations differ meaningfully in genetic barrier, not merely in dosing frequency.

15. Boosted HIV protease inhibitors (for example, ritonavir-boosted darunavir) are described as high genetic barrier agents. What underlies this high barrier?

A) A single primary active-site mutation abolishes drug binding, but that mutation almost never occurs in vivo.
B) Clinically significant protease inhibitor resistance typically requires accumulation of multiple primary mutations plus secondary accessory mutations, so several substitutions must coexist before susceptibility is meaningfully lost.
C) Protease inhibitors are not subject to resistance because the protease enzyme is too highly conserved to tolerate any mutation.
D) The ritonavir boost chemically prevents the protease gene from mutating during replication.
E) Resistance depends solely on a single integrase mutation shared with the INSTI class.

ANSWER: B

Rationale:

Option B is correct. Protease inhibitor resistance is characterized by stepwise accumulation of multiple primary mutations in the active site or substrate cleft, supplemented by secondary/accessory mutations that restore replication capacity. Because roughly 3 to 5 or more mutations are usually needed for clinically significant resistance, boosted protease inhibitors such as darunavir/ritonavir have high genetic barriers.

Option A: Option A is incorrect. Protease inhibitor resistance is multi-mutational, not the product of a single decisive primary mutation.
Option C: Option C is incorrect. The protease can and does tolerate resistance mutations; the barrier is high but not absolute.
Option D: Option D is incorrect. Ritonavir boosts protease inhibitor levels pharmacokinetically; it does not prevent the viral gene from mutating.
Option E: Option E is incorrect. Protease inhibitor resistance involves protease mutations, not a single shared integrase mutation.

16. A treatment-naive chronic hepatitis B virus (HBV) patient is started on lamivudine monotherapy. Applying the resistance principles established earlier in this set, which outcome is most predictable, and by what mutation?

A) Durable suppression with essentially no resistance, because HBV mutates too slowly to develop lamivudine resistance.
B) Resistance only if the patient is co-infected with HIV, because HBV alone cannot select reverse transcriptase mutations.
C) High cumulative resistance — reaching roughly 70% by five years — driven by the rtM204V/I mutation (methionine-to-valine/isoleucine at reverse transcriptase position 204), typically with the compensatory rtL180M.
D) Resistance confined to the cytomegalovirus UL97 phosphotransferase pathway.
E) Resistance through the integrase Q148H mutation, identical to the HIV INSTI pathway.

ANSWER: C

Rationale:

Option C is correct. HBV replicates through a reverse-transcribed RNA intermediate and, under single-drug pressure, predictably selects the rtM204V/I mutation conferring lamivudine resistance, usually with the compensatory rtL180M that restores replication capacity. Lamivudine monotherapy resistance reached about 70% by five years — one of the most dramatic examples of resistance emergence in clinical virology, and exactly what the monotherapy/low-barrier principle predicts.

Option A: Option A is incorrect. Although HBV mutates more slowly than HIV, sustained monotherapy still selects high-level resistance; the rtM204 pathway is well documented.
Option B: Option B is incorrect. HBV selects rtM204V/I on its own under lamivudine pressure; HIV co-infection is not required.
Option D: Option D is incorrect. UL97 is the cytomegalovirus ganciclovir-resistance gene, unrelated to HBV reverse transcriptase resistance.
Option E: Option E is incorrect. Q148H is an HIV integrase mutation; HBV lamivudine resistance is an rtM204 reverse transcriptase event.

17. A patient with chronic HBV and a prior history of lamivudine therapy needs a high-barrier agent. Using the resistance-barrier reasoning developed earlier, which choice best fits, and why?

A) Telbivudine, because L-nucleoside analogs are unaffected by prior lamivudine exposure.
B) Adefovir monotherapy, because it shares no resistance pathway with any other agent.
C) Entecavir, because prior lamivudine resistance has no bearing on entecavir susceptibility.
D) Lamivudine again at a higher dose, because dose escalation overcomes rtM204V/I resistance.
E) Tenofovir, because it has the highest resistance barrier of any approved HBV agent — no resistance confirmed after 15+ years — and is preferred over entecavir when lamivudine resistance may pre-exist.

ANSWER: E

Rationale:

Option E is correct. Tenofovir (TDF or TAF) has the highest genetic barrier of any approved HBV agent, with no confirmed clinical resistance after more than 15 years of use. It is specifically preferred over entecavir in patients with prior lamivudine/telbivudine exposure, because pre-existing rtM204V/I plus rtL180M lowers the additional barrier entecavir needs (entecavir requires those mutations plus one more), elevating entecavir resistance risk in that setting.

Option A: Option A is incorrect. Telbivudine is an L-nucleoside analog cross-affected by the rtM204 pathway, so prior lamivudine resistance compromises it.
Option B: Option B is incorrect. Adefovir is a low-barrier agent (about 30% resistance by year five as monotherapy) and is not the high-barrier choice.
Option C: Option C is incorrect. Prior lamivudine resistance substantially raises entecavir resistance risk, so it is not the preferred agent in that history.
Option D: Option D is incorrect. Dose escalation does not overcome rtM204V/I; this contradicts the discrimination-resistance principle.

18. For most patients treated with a modern pangenotypic hepatitis C virus (HCV) regimen such as sofosbuvir-velpatasvir, baseline resistance-associated substitution (RAS) testing is not routinely required. Which principle best explains this?

A) Sofosbuvir, an NS5B nucleotide polymerase inhibitor with an exceptionally high resistance barrier, anchors these combinations and preserves cure rates above 95% even when baseline NS5A or NS3 RASs are present.
B) HCV does not mutate, so resistance-associated substitutions never occur and testing would always be negative.
C) The regimens are mutagenic to HCV, eliminating resistant variants before they can be selected.
D) Pangenotypic regimens contain five or more drugs, making any single resistance pathway irrelevant.
E) Resistance testing is omitted only because the assays are unavailable, not for any pharmacological reason.

ANSWER: A

Rationale:

Option A is correct. Sofosbuvir is an NS5B nucleotide inhibitor with an exceptionally high resistance barrier; it anchors pangenotypic combinations (for example, sofosbuvir-velpatasvir) so that cure rates exceed 95% even when baseline NS5A or NS3 RASs exist. That high-barrier anchor is why routine baseline RAS testing is unnecessary for most treatment-naive patients, though NS5A RAS testing retains a role in re-treatment after prior failure.

Option B: Option B is incorrect. HCV has one of the highest mutation rates in virology and generates extensive baseline diversity; RASs do occur.
Option C: Option C is incorrect. These DAAs act by inhibition and selection, not by mutagenizing HCV.
Option D: Option D is incorrect. Pangenotypic regimens are typically two- or three-drug combinations; the explanation is the high-barrier sofosbuvir anchor, not a five-drug count.
Option E: Option E is incorrect. The omission is pharmacological (high cure rates despite baseline RASs), not a matter of assay availability.

19. An immunocompromised patient has progressive, non-healing mucocutaneous herpes simplex virus (HSV) lesions despite adequate acyclovir. Genotyping shows a thymidine kinase (TK)-null phenotype. Why does this single mechanism affect several drugs at once, and what is the appropriate pivot?

A) The TK-null mutation affects only acyclovir; switching to valacyclovir or famciclovir restores activity because they bypass viral TK.
B) Because acyclovir, valacyclovir, penciclovir, and famciclovir all require viral TK for activation, a TK-null mutation confers cross-resistance to the entire TK-dependent class — so the pivot is foscarnet, which inhibits the viral DNA polymerase without requiring TK.
C) TK-null HSV is best treated by increasing the acyclovir dose, since the defect is only partial under all circumstances.
D) The TK-null phenotype reflects a host enzyme deficiency, so changing the antiviral will not help.
E) TK-null mutations confer resistance to foscarnet specifically, so cidofovir must be used first-line in every case.

ANSWER: B

Rationale:

Option B is correct. Acyclovir, valacyclovir, penciclovir, and famciclovir all depend on viral thymidine kinase for the initial phosphorylation that activates them. A TK-null mutation therefore knocks out the entire TK-dependent class simultaneously. The standard pivot is foscarnet, which directly inhibits the viral DNA polymerase at the pyrophosphate-binding site and does not require viral TK; cidofovir, activated by cellular enzymes, is an alternative for refractory cases.

Option A: Option A is incorrect. Valacyclovir and famciclovir are prodrugs of TK-dependent agents (acyclovir and penciclovir), so they are also defeated by a TK-null mutation.
Option C: Option C is incorrect. A TK-null phenotype cannot be overcome by dose escalation, because the activating enzyme is absent.
Option D: Option D is incorrect. The defect is in viral TK, not a host enzyme; switching to a TK-independent agent (foscarnet) is effective.
Option E: Option E is incorrect. Foscarnet does not require TK and remains active against TK-null strains; it is the appropriate first pivot, not contraindicated.

20. A transplant recipient with suspected ganciclovir-resistant cytomegalovirus (CMV) has genotyping that shows an isolated UL97 (CMV phosphotransferase) mutation with no UL54 (CMV DNA polymerase) mutation. What does this pattern imply for management?

A) Both foscarnet and cidofovir will also be inactive, because UL97 mutations confer pan-resistance to all CMV agents.
B) The result indicates host pharmacokinetic failure rather than resistance, so no drug change is warranted.
C) Ganciclovir resistance is excluded, because only UL54 mutations cause ganciclovir resistance.
D) Ganciclovir resistance is present, but foscarnet and cidofovir remain active because neither requires UL97 for activation — and maribavir (which inhibits UL97 through a distinct site) retains activity against many UL97 mutations.
E) The patient must remain on ganciclovir at the same dose, since UL97-only mutations do not reduce ganciclovir efficacy.

ANSWER: D

Rationale:

Option D is correct. UL97 phosphorylates ganciclovir to its monophosphate; an isolated UL97 mutation impairs that activation, conferring ganciclovir resistance while leaving foscarnet and cidofovir fully active, since neither depends on UL97. Maribavir inhibits UL97 kinase through a binding site distinct from ganciclovir and retains activity against many UL97 mutations (notably at codons 460 and 595).

Option A: Option A is incorrect. UL97-only mutations do not confer pan-resistance; foscarnet and cidofovir remain active.
Option B: Option B is incorrect. A defined resistance mutation is virologic resistance, not pharmacokinetic failure, although drug levels and adherence should always be confirmed first.
Option C: Option C is incorrect. UL97 mutations are in fact the primary ganciclovir-resistance pathway; resistance is not excluded.
Option E: Option E is incorrect. A UL97 mutation reduces ganciclovir activation, so continuing the same ganciclovir dose is inappropriate.

21. Across herpesviruses, SARS-CoV-2, and many other viruses, antiviral resistance emerges preferentially in one patient population. Which population, and what is the unifying mechanistic reason?

A) Vaccinated patients, because vaccine-induced antibodies drive escape mutations at antiviral drug targets.
B) Pediatric patients, because immature renal clearance produces supratherapeutic drug levels that select resistance.
C) Severely immunocompromised patients, because they cannot clear virus immunologically and therefore require prolonged antiviral therapy, creating sustained drug selection pressure without the immune co-factor that eliminates residual low-level replication.
D) Patients with brief, fully adherent treatment courses, because rapid viral suppression paradoxically selects resistance.
E) Immunocompetent patients with acute self-limited infections, because high peak viral loads guarantee resistance.

ANSWER: C

Rationale:

Option C is correct. Resistance emerges most often in severely immunocompromised patients (advanced AIDS, transplant recipients) because they cannot immunologically clear virus and need prolonged antiviral therapy. This combination — sustained drug selection pressure plus the absence of immune clearance of residual replication — is the unifying reason resistance arises preferentially in this group across acyclovir-resistant HSV/VZV, ganciclovir-resistant CMV, and nirmatrelvir- or remdesivir-resistant SARS-CoV-2.

Option A: Option A is incorrect. Vaccine-induced antibodies target surface antigens, not antiviral drug-binding sites, and do not drive antiviral drug resistance.
Option B: Option B is incorrect. Resistance is tied to prolonged therapy in immune-deficient hosts, not to pediatric renal clearance producing high levels.
Option D: Option D is incorrect. Short, fully suppressive, adherent courses reduce resistance risk; sustained subtherapeutic or prolonged pressure increases it.
Option E: Option E is incorrect. Immunocompetent hosts with self-limited infection clear residual virus immunologically and are at low resistance risk.

22. Pandemic-preparedness planning for a novel RNA virus draws directly on the resistance principles established for HIV and HCV. Which strategy most directly applies the genetic-barrier concept to an emerging pathogen?

A) Reserve a single most-potent antiviral as monotherapy and stockpile only that agent, to simplify distribution during a surge.
B) Delay all resistance surveillance until widespread resistance is documented, then introduce combination therapy.
C) Treat only immunocompetent patients with antivirals, since they are the main source of resistance emergence.
D) Rely on dose escalation of one agent to outpace resistance, avoiding the complexity of multiple drugs.
E) Combine mechanistically distinct agents — for example, a main protease (Mpro) inhibitor with an RNA-dependent RNA polymerase inhibitor — and maintain a mechanistically diverse stockpile, so the virus would need simultaneous resistance at multiple targets.

ANSWER: E

Rationale:

Option E is correct. The genetic-barrier principle applied to pandemics means combining mechanistically distinct agents (for example, an Mpro inhibitor such as nirmatrelvir with an RNA-dependent RNA polymerase inhibitor such as remdesivir or molnupiravir) so a virus must acquire simultaneous resistance at multiple targets, and maintaining a mechanistically diverse stockpile so resistance to one agent does not collapse the whole strategy.

Option A: Option A is incorrect. Single-agent stockpiles create a single point of failure — exactly the monotherapy trap the resistance principles warn against.
Option B: Option B is incorrect. Surveillance should precede widespread deployment, not wait until resistance is already established.
Option C: Option C is incorrect. Immunocompromised patients, not immunocompetent ones, are the primary source of resistance emergence and warrant the most intensive monitoring.
Option D: Option D is incorrect. Dose escalation of one drug does not raise the genetic barrier the way mechanistically distinct combination therapy does.